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A double-blind comparison of meglumine iodamide and Renografin 60 (52% meglumine diatrizoate and
8% sodium diatrizoate) for bolus excretory urography was performed. Doses of 0.8 cc/kg. to a maximum of
55 cc were administered to fifty patients, twenty-five receiving each drug.
There is a suggestion that iodamide may be superior to diatrizoate in pyelocalyceal opacification while
being equal to diatrizoate in parenchymal opacification and in types and severity of side-effects.
INTRODUCTION
lodamide is a new contrast agent for excretory urography which is used in Europe
but has not as yet been approved for use in the United States. It is a triiodinated
benzoic acid derivative differing from diatrizoate by the substitution of a
-CONHCH3 in position three ofthe benzoic ring for the acetyl-amino radical ofthe
diatrizoate (Fig. 1). Extensive animal studies of the pharmacology and toxicity of
iodamide have shown it to be similar to the standard contrast agents now used for
urography [1]. The purpose of the present study was to conduct a double-blind
comparison of the side-effects and the quality of the urograms following bolus
injection ofmeglumine iodamide and Renografin 60 (meglumine diatrizoate 52%and
sodium diatrizoate 8%).
Materials and Methods
Bolus excretory urograms were performed in fifty consecutive adult out-patients
referred for this examination. Excluded from this group were patients who were
pregnant, had a history of hypersensitivity to contrast agents or iodine compounds,
had received a cholecystocholangiographic agent within one month ofthe study, had
severely impaired renal function (less than 10 mm per minute creatinine clearance
and/or 50% elevation above normal of both BUN and serum creatinine), had
impaired liver function (serum bilirubin above 3 mg %), or had a history ofcardio-
vascular disease or electrocardiographic abnormalities prior to enrollment. In addi-
tion, moribund patients and those with hyperthyroidism, homozygous sickle cell
disease, pheochromocytoma and multiple myeloma were not included in the study.
All patients received complete physical examinations before the study and 24 and 72
hours after it. At these times, blood was also drawn for CBC, serum creatinine,
SGOT, and SMA-12, and a urinalysis was performed. Any abnormalities after 72
hours were followed at weekly intervals until a return to normal. Complete 12 lead
electrocardiograms were done before, during, and after the injection on twenty-four
of these patients. All patients had an initial opthalmologic evaluation and ten ofthese
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patients had an ophthalmologic examination six months later. The contrast agents
were packaged in vials, labelled in code. Twenty-five vials contained 55 cc of 65%
meglumine iodamide containing the equivalent of 300 mg per ml of organically-
bound iodides, and, therefore, 15 grams of iodine. Twenty-five vials contained 50 cc
of Renografin 60, which had the equivalent of 288 mg per ml or organically-bound
iodide, and therefore, 14.4 grams of iodine.
The drugs were administered in a double-blind manner. Individual doses were
calculated on the basis of 0.8 ml/kg body weight with a maximum dose of 55 cc.
After a preliminary film had been obtained, the contrast was injected as a bolus
(injection time of ½/2-1 minute). Films were obtained at one, three, five, ten, twenty
and thirty minutes after completion of injection and additional radiographs at later
intervals were obtained as indicated. Each film was evaluated as to technical ade-
quacy by a radiologist who was unaware of the agent used. In those films judged
adequate, the radiographic density ofnephrogram, calices, pelvis, ureter, and bladder
was graded from 0 representing no opacification, to 2 representing dense opacifica-
tion. Three different uroradiologists each graded one-third ofthe cases on a random
basis.
Results
Drugs were administered in a double-blind manner: meglumine iodamide was
given to eighteen males and seven females ranging in age from 23 to 74 years (average
51.5 years); Renografin 60 was given to fifteen males and ten females ranging in age
from 18 to 77 years (average 45.6 years). The total doses in the meglumine iodamide
group ranged from 37 to 50 ml (average 48.7 ml) while those in the Renografin 60
group ranged from 30.9 to 50 ml (average 48 ml).
The overall performance of the contrast agent wasjudged "satisfactory" in twenty-
three of the twenty-five patients receiving each agent. A radiologic diagnosis was
possible in twenty-four of the twenty-five patients in each group; in each case in
which a radiologic diagnosis was not possible the drug performance had also been
graded "unsatisfactory." Of the twenty-five patients who received meglumine iodam-
ide, ten had normal excretory urograms. The other fifteen patients had genitourinary
tract conditions which were diagnosed as renal calculi, ureteric obstructions, pros-
tatic enlargement, hydronephrosis and trabeculated bladder. Of the twenty-five
patients who received Renografin 60, fifteen had normal excretory urograms. The
other twelve had genitourinary tract conditions which were diagnosed as renal
calculi, renal and ureteric displacement, nephrectomy, caliectasis, renal scarring and
prostatic enlargement.
Laboratory abnormalities for each group are listed in Table 1. It should be noted
that abnormalities in a given test were counted separately each time they occurred. Of
the twenty-five patients treated with meglumine iodamide, thirteen patients had a
total of twenty-seven laboratory abnormalities. Of the twenty-five patients treated
with Renografin 60, ten had a total of twenty-two abnormalities.
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TABLE I
Laboratory Abnormalities Attributable to Drug
PT Abnormality Time PT Abnormality Time
004 BUN t 24 hours 003 SGOT t 24 hours and 72 hours
005 Lymphocytes 1 72 hours 009 Neutrophils 1 24 hours
014 Serum glucose t 24 hours Lymphocytes t 24 hours
018 Urinary protein present 24 hours 013 SGOT 1 24 hours
Urinary WBC present 72 hours Alkaline phosphatase t 24 hours and 72 hours
021 Serum calcium 1 24 hours 023 Urine specific gravity t 24 hours
022 Urinary protein present 24 hours 029 Eosinophils t 24 hours
024 Serum calcium 1 24 hours and 72 hours 034 Neutrophils t 24 hours
Lymphocytes 1 24 hours
025 SOOT 1 72 hours BUN t 24 hours
Serum creatinine 1 24 hours and 72 hours
036 Monocytes 1 24 hours
028 Lymphocytes 1 24 hours
Neutrophils t 24 hours 038 S. protein 124 hours
BUN 1 24 hours Serum albumin 1 24 hours
033 Lymphocytes 1 24 hours 052 Urinary RBC present 24 hours and 72 hours
044 BUN 124 hours Urinary WBC present 24 hours
Serum uric acid t 24 hours Basophils
t 24 hours
054 BUN t 24 hours
051 SGOT 124 hours
Serum albumin 1 24 hours and 72 hours
Serum creatinine t 24 hours and 72 hours
053 Basophils t 24 hours and 72 hours
BUN 1 72 hours
Serum calcium t 72 hours
Note: The laboratory abnormalities for the two drugs are comparable. No abnormalities persisted beyond seventy-two
hours.
Adverse reactions were comparable in frequency, severity, and nature for the two
drug groups. Among the twenty-five patients given the meglumine iodamide, three
males and three females representing a total of six patients had eight adverse
reactions: two patients developed both pruritus and urticaria, two developed nausea
and vomiting, one patient had nausea and one patient had a decrease in blood
pressure. The patient with a drop in blood pressure had a controlvalue of 107/50 and
had a drop in blood pressure to 80/20 at 30 minutes after injection. The patient was
treated with Ringer's lactate solution and returned to a control blood pressure within
the hour.
Of the twenty-five patients who received Renografin 60, six (three males and three
females) had a total of six adverse reactions: nausea and vomiting in one patient,
nausea in one, vomiting in two, blood pressure increase in one, and blood pressure
decrease requiring no treatment in one.
The electrocardiograms done before, during, and ten minutes after the injection of
eleven patients given meglumine iodamide and thirteen patients given Renografin 60
showed no significant abnormalities at any time foreithergroup ofpatients. Ophthal-
mologic examinations were done for fifty patients at the time oftreatment and for ten
of the fifty patients approximately six months later. These studies showed abnormali-




Degree of Opacification-All Sites
Time Parenchyma Calices Pelvis Ureters Bladder
(min.) Opacity lod Ren lod Ren Iod Ren Iod Ren lod Ren
I Dense (2) 7 10 2* 0 2 0 2 0 2 0
Faint (1) 16 14 1 0 0 0 0 0 0 0
None (0) 2 0 22 24 23 24 23 24 23 24
3 Dense (2) 10 7 17** 7 19** 7 9 3 3 0
Faint (1) 14 16 6 10 4 9 6 8 4 4
None (0) 1 0 2 6 2 7 10 12 18 19
5 Dense (2) 7 8 20 15 21 18 14 7 5 2
Faint (1) 14 16 5 9 2 6 7 15 14 15
None (0) 4 0 0 0 2 0 4 2 6 7
10 Dense (2) 8 6 20 16 22 17 15 10 16 8
Faint (1) 12 18 4 8 2 7 6 12 5 13
None (0) 4 0 0 0 0 0 3 2 3 3
Dense (2) 5 3 17 12 17 15 15 9 15 13
Faint (1) 12 15 2 7 1 3 1 8 4 6
None (0) 2 1 0 0 1 1 3 2 0 0
20 Dense (2) 5 0 13 9 15 11 9 4 15* 13
Faint (1) 9 16 5 8 2 6 8 12 3 2
None (0) 4 1 0 0 1 0 1 1 0 2
30 Dense (2) 4 2 13 10 16* 10 10 4 20 19
Faint (1) 15 20 10 12 7 13 12 18 2 4
None (0) 4 2 0 2 0 1 1 2 1 1
* = p <.05
** = p <.01
Note: At all sites there is a definite trend toward denser opacification with iodamide than with Renografin. At several
sites, as indicated, this difference was statistically significant.
The degree ofopacification produced in each site foreach drug is shown in Table 2.
The denser of bilateral sites was chosen for statistical analysis in this table. As can be
seen from the table, every patient did not have a film at each time due to individual
modifications necessary for diagnostic accuracy. In Table 3 the time to first dense
opacification is shown for the seventeen patients who received meglumine iodamide
and the eleven patients who received Renografin 60 and who also had every required
film. For the purpose of statistical analysis each of the two paired structures was
treated as a separate entity in Table 3. In addition, those patients who did not have
dense opacification at any time in a given portion of the urinary tract were not
included in that portion of the statistical analysis.
In assessing the results presented in Tables 2 and 3, the Wilcoxan model of
nominal-ordinal association was used. Inference was calculated by theapplication of
the Mann-Whitney U-Test [2] in order to determine whether knowledge of the
radiopaque material could predict the degree ofdenseness ofthe image (Table 2) or
the time to first dense opacification (Table 3). In Table 2, at all sites in which there
was a significant difference in the opacification (at varying P values as shown)
produced by the two drugs, iodamide produced the better results. Similarly in Table
3, meglumine iodamide produced a statistically significant (at varying P values as
shown) earlier first dense opacification of all sites except parenchyma.
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TABLE 3
Time to First Dense Opacification
I 3 5 10 20 30 Never Significance
I 13 4 0 0 0 0 17 N.S.
Parenchyma
R 11 1 2 2 0 0 6
1 2 20 1 2 1 0 8 *
Calices
R 0 3 7 3 0 0 9
1 2 22 2 2 1 0 5 *
Pelves
R 0 3 12 3 1 0 3
1 2 7 10 2 0 0 13 ***
Ureters
R 0 1 0 5 4 0 12
1 2 1 2 7 2 1 2 **
Bladder
R 0 0 0 2 7 0 2
** = p <.01
= p <.001
Note: At all sites except for the parenchyma there is a statistically significant earlier first dense opacification with
iodamide (I = iodamide, R = Renografin 60).
DISCUSSION
In our study the side-effects of iodamide were comparable to those of Renografin.
This result is similar to that ofdeLange and Hermans, who compared side-effects of
iodamide and diatrizoate in excretory urography in 1,418 patients [3]. They used a
dose comparable to ours and found some kind of side-effect in 20% of the patients
who received each agent. They found no correlation with sex or age of the patient.
Other studies ofiodamide have found a variable incidence ofadverse reaction [4,5,6]
but none of these represented a comparative trial with another agent.
The data of our clinical trial indicates that the two agents are equal for parenchy-
mal opacification but that iodamide is superior for opacifying the calices and pelvis.
For the ureters and bladder, there is a clear trend towards superior performance by
iodamide but not with the same degree ofstatistical confidence as was demonstrated
for the calices and pelvis.
The standard contrast agents such as Renografin 60whichwasusedinthisstudyare
excreted by the normal kidney almost ifnotentirely by glomerular filtration. Tubular
secretion does not play a significant role [7]. Work in both animals [8] and humans
[9] has suggested that, in contrast, iodamide may also be secreted by a normal kidney
by tubular secretion. The data in Tables 2 and 3 ofour study suggest that iodamide is
superior to diatrizoate both in the degree ofopacification and in the time ofearliest
dense opacification. If tubular secretion occurs with iodamide but does not occur
with diatrizoate, a rapid elimination and denser opacification would be expected for
iodamide.
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